Bernd Schnabl mainly investigates Immunology, Liver disease, Alcoholic liver disease, Cirrhosis and Fatty liver. He combines subjects such as REG3G, Steatohepatitis and Hepatic stellate cell with his study of Immunology. His research integrates issues of Microbiome, Liver injury, Hepatocyte, Hepatitis and Chronic liver disease in his study of Liver disease.
His research investigates the connection between Alcoholic liver disease and topics such as Dysbiosis that intersect with issues in Microbiology and Metabolome. His work carried out in the field of Cirrhosis brings together such families of science as Nonalcoholic fatty liver disease, Decompensation and Ascites. His study looks at the relationship between Fatty liver and fields such as Fibrosis, as well as how they intersect with chemical problems.
Liver disease, Internal medicine, Immunology, Alcoholic liver disease and Cirrhosis are his primary areas of study. His studies in Liver disease integrate themes in fields like Microbiome, Gut flora, Dysbiosis, Alcoholic hepatitis and Fatty liver. His Internal medicine study incorporates themes from Gastroenterology and Endocrinology.
His research on Immunology often connects related areas such as Hepatic stellate cell. His research in Alcoholic liver disease focuses on subjects like Steatohepatitis, which are connected to Proinflammatory cytokine. Bernd Schnabl works on Cirrhosis which deals in particular with Chronic liver disease.
His primary scientific interests are in Liver disease, Gut flora, Microbiome, Alcoholic hepatitis and Immunology. His Liver disease research integrates issues from Cirrhosis, Alcoholic liver disease, Dysbiosis and Fatty liver. His work in the fields of Cirrhosis, such as Chronic liver disease, overlaps with other areas such as Lachnospiraceae.
His Dysbiosis study combines topics from a wide range of disciplines, such as Steatohepatitis and Intestinal permeability. His work focuses on many connections between Microbiome and other disciplines, such as Nonalcoholic fatty liver disease, that overlap with his field of interest in Liver biopsy, FGF21, Odds ratio and Receptor. The study incorporates disciplines such as Gastroenterology and Endocrinology in addition to Internal medicine.
His main research concerns Liver disease, Dysbiosis, Alcoholic hepatitis, Gut flora and Immunology. The concepts of his Liver disease study are interwoven with issues in Alcoholic liver disease, Pathogenesis, Disease, Fatty liver and Intestinal permeability. His studies deal with areas such as Fibrosis and Cirrhosis as well as Fatty liver.
The various areas that Bernd Schnabl examines in his Dysbiosis study include Gastroenterology and Antibiotics. His Gut flora research includes elements of Proinflammatory cytokine and Liver injury, Pharmacology. His Immunology research incorporates themes from Chronic liver disease, Microbiome and Hepatocyte.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth.
Sergei I. Grivennikov;Kepeng Wang;Daniel Mucida;C. Andrew Stewart.
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Rajiv Jalan;Javier Fernandez;Reiner Wiest;Bernd Schnabl.
Journal of Hepatology (2014)
Interactions between the intestinal microbiome and liver diseases.
Bernd Schnabl;David A. Brenner.
Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
Kouichi Miura;Kouichi Miura;Yuzo Kodama;Sayaka Inokuchi;Bernd Schnabl.
Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits
Katharina Brandl;George Plitas;Coralia N. Mihu;Coralia N. Mihu;Carles Ubeda.
Enteric dysbiosis associated with a mouse model of alcoholic liver disease
Arthur W. Yan;Derrick E. Fouts;Johannes Brandl;Johannes Brandl;Peter Stärkel.
Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
Sungsoon Fang;Jae Myoung Suh;Shannon M Reilly;Elizabeth Yu.
Nature Medicine (2015)
MyD88-mediated signals induce the bactericidal lectin RegIIIγ and protect mice against intestinal Listeria monocytogenes infection
Katharina Brandl;George Plitas;Bernd Schnabl;Ronald P. DeMatteo.
Journal of Experimental Medicine (2007)
Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease
Rohit Loomba;Victor Seguritan;Weizhong Li;Tao Long.
Cell Metabolism (2017)
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut.
Ekihiro Seki;Bernd Schnabl.
The Journal of Physiology (2012)
Journal of Hepatology
(Impact Factor: 30.083)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: